Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease
NCT04112810
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
51
Enrollment
OTHER
Sponsor class
Conditions
Hematologic Malignancies
Interventions
DRUG:
Tildrakizumab
Sponsor
Medical College of Wisconsin